This page collects WhisperX intelligence signals tagged #Drug Pricing. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
The White House is privately circulating draft legislative text for its drug pricing policy to more than a dozen major pharmaceutical companies, signaling a critical push to secure industry backing. This move, confirmed by people familiar with the meetings, represents a concrete step beyond public rhetoric, placing det...
Doctors Without Borders has launched a sharp public rebuke of Gilead Sciences, labeling the pharmaceutical giant's refusal to sell a groundbreaking HIV prevention drug directly to humanitarian organizations as 'unconscionable.' The criticism centers on lenacapavir, a long-acting injectable that offers virtually complet...
Major pharmaceutical companies are delaying the launch of new medicines in Europe, a strategic shift driven by intensifying pressure from the United States market. According to a Reuters report, the industry is grappling with the White House's push to lower prescription drug costs and policy shifts from the Trump admin...
Major pharmaceutical companies are strategically delaying the launch of new medicines in Europe, a direct response to intensifying pressure to lower drug prices in the United States. The industry is maneuvering to protect its highest-margin market, where prices have traditionally been significantly higher than in other...
Novo Nordisk is launching a subscription plan that offers its blockbuster obesity drugs at a lower cash price, but only to patients who enroll through specific telehealth providers. This direct-to-consumer pricing strategy, bypassing traditional insurance and pharmacy benefit managers, immediately raises questions abou...
The Trump administration has prepared a draft executive order that would impose a 100% tariff on imports of patented medications and their active ingredients. This aggressive trade measure, targeting a critical sector of the pharmaceutical supply chain, could be announced as soon as Thursday, signaling a major escalati...
The Trump administration is reportedly preparing to impose new tariffs on a select group of pharmaceutical companies, signaling a significant escalation in its trade and pricing pressure on the drug industry. This move comes amid stalled negotiations, indicating that the White House is ready to deploy punitive trade me...
The Trump administration has prepared an executive order to impose a 100% tariff on imports of patented medicines and their active pharmaceutical ingredients, a move that could be announced as soon as Thursday. This aggressive trade action directly targets the pharmaceutical supply chain, though the timeline and final ...
The Trump administration is reportedly considering a hardball tactic to force pharmaceutical companies to the negotiating table: imposing tariffs on drugmakers who refuse to sign new 'Most Favored Nation' (MFN) pricing agreements. This potential move signals a significant escalation in the administration's push to lowe...
The Trump administration is expanding its pressure campaign on drug prices, now targeting smaller pharmaceutical companies with confidential negotiations. According to sources, including a White House official, these new talks offer a critical pathway for smaller firms to pledge lower prices and potentially avoid the l...
The Trump administration has launched a new, aggressive front in its campaign against the pharmaceutical industry, announcing 100% tariffs on imported brand-name prescription drugs. This move directly targets the core business model of multinational drugmakers, aiming to force a fundamental shift in where medicines are...
The Trump administration is wielding newly announced 100% tariffs as a powerful cudgel, pushing both large and small pharmaceutical companies into confidential pricing and manufacturing agreements. This aggressive use of trade policy marks a significant escalation in the government's direct pressure on the drug industr...
A renewed legislative push in Colorado aims to carve out a major exception to the state's drug pricing oversight, potentially shielding a significant category of medicines from future cost controls. For the second time in two years, a bill is advancing that would exempt all orphan drugs—treatments for rare diseases—fro...
A new analysis reveals Merck's experimental HIV prevention pill, MK 8527, could be mass-produced for less than $5 per patient annually. This strikingly low potential cost is fueling pressure on the pharmaceutical giant to license the drug for broad access in low- and middle-income countries, where the HIV burden is hig...
Stephen Ubl, the long-serving CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), is set to resign, creating a sudden leadership vacuum at the industry's most powerful lobbying organization. His departure, first reported by Endpoints News, comes as the pharmaceutical sector faces intense political ...
Steve Ubl is stepping down as CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), the powerful trade group representing the brand-name drug industry. His departure, planned by year's end, marks the end of a more than decade-long tenure defined by navigating the industry through its most politically...
The Trump administration's push to force pharmacy benefit managers (PBMs) to disclose their secretive drug pricing data is meeting a coordinated legal and lobbying counteroffensive. The industry, which generates billions in annual profits as the gatekeepers of prescription drug spending, is warning that a proposed Depa...
A powerful coalition of pharmacy benefit manager (PBM) and health insurance lobbyists is aggressively fighting a new federal proposal designed to force transparency into the opaque world of prescription drug pricing. The pushback signals a high-stakes battle over a rule that aims to reveal the complex rebates and fees ...
The Trump administration on Thursday announced completion of a landmark pricing agreement with Regeneron Pharmaceuticals, marking what the White House described as the culmination of its first round of pharmaceutical negotiating deals. The announcement positions the Regeneron accord as the final piece of an initial bat...
The FDA is revisiting a rare cancer treatment it previously rejected just months ago, according to sources familiar with the matter, raising questions about the regulatory process and broader concerns about political pressure on drug reviews. The reconsideration comes as FDA leadership faces mounting accusations of po...